ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Parasite and Host
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1671048
This article is part of the Research TopicHost Cell Entry by Malaria ParasitesView all 3 articles
The reticulocyte restriction: invasion ligand RBP1a of Plasmodium vivax targets human TfR1, prohibitin-2, and basigin
Provisionally accepted- 1Department of Immunology & Theranostics, City of Hope, Beckman Research Institute, Arthur Riggs Diabetes and Metabolism Research Insitute, Duarte, California, United States
- 2Global Scholars Program, City of Hope, Beckman Research Institute, Duarte, California, United States
- 3PhD Program in Biotechnology, Universidad Nacional de Colombia, Bogotá, Colombia
- 4Grupo de Investigación Básica en Biología Molecular e Inmunología (GIBBMI), Fundacion Instituto de Inmunologia de Colombia, Bogotá, Colombia
- 5Department of Immunology & Theranostics, City of Hope Beckman Research Institute, Duarte, United States
- 6Health Sciences Faculty, Universidad de Ciencias Aplicadas y Ambientales, Bogotá, Colombia
- 7Microbiology Department, Universidad Nacional de Colombia Facultad de Medicina, Bogotá, Colombia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Plasmodium vivax is the most widespread cause of malaria outside Africa. Developing effective controls is challenging because P. vivax exclusively invades reticulocytes, immature erythrocytes that are scarce and short-lived. This limits opportunities to culture the parasite and investigate the receptor-ligand interactions crucial for host cell invasion. Methods: The erythroid cell lines JK-1 and BEL-A were evaluated in vitro as reticulocyte surrogates to assess their susceptibility to P. vivax invasion. Comparative membrane proteomics of these cell lines, reticulocytes, and mature erythrocytes were performed using quantitative liquid chromatography–mass spectrometry (LC-MS). Specific interactions between the parasite ligand PvRBP1a (residues 158–650) and candidate host receptors were identified by TurboID proximity labeling and validated through ELISA binding assays. Results: We confirmed that the JK-1 cell line supports P. vivax invasion and demonstrated for the first time that BEL-A cells are similarly susceptible, establishing both as effective surrogate models. Membrane proteomics identified several receptor candidates potentially involved in selective host-cell entry. In addition to known receptors, including transferrin receptor protein 1 (TfR1/CD71), CD98hc, and basigin (BSG), novel receptor candidates such as prohibitin-2 (PHB2), CAT-1 (SLC7A1), ATB(0) (SLC1A5), CD36, integrin beta-1 (ITGB1), and metal transporter CNNM3 were discovered. Proximity labeling with a recombinant PvRBP1a (158–650)-TurboID fusion protein confirmed the known interactions with TfR1 and BSG, and additionally identified PHB2 as a novel interacting partner. Notably, this is the first report implicating PHB2 as a co-receptor for P. vivax invasion. Conclusion: Our findings provide novel insights into the molecular mechanisms underlying reticulocyte restriction in P. vivax. The JK-1 and BEL-A cell lines represent valuable platforms for dissecting receptor–ligand interactions during parasite invasion and for advancing the development of targeted therapeutic antimalarial strategies.
Keywords: Plasmodium vivax, parasite invasion, Erythroid cell lines, Membrane proteomics, receptor-ligand interactions, LC-MS proteomics
Received: 22 Jul 2025; Accepted: 03 Sep 2025.
Copyright: © 2025 Molina-Franky, Roeth, Ararat-Sarria, Patarroyo and Kalkum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Manuel Alfonso Patarroyo, Grupo de Investigación Básica en Biología Molecular e Inmunología (GIBBMI), Fundacion Instituto de Inmunologia de Colombia, Bogotá, Colombia
Markus Kalkum, Department of Immunology & Theranostics, City of Hope Beckman Research Institute, Duarte, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.